Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 641-648

  Unsoy, Gozde ^a   Yalcin, Serap ^b   Khodadust, Rouhollah ^a   Mutlu, Pelin ^a   Onguru, Onder ^c   Gunduz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b AHI EVRAN UNIVERSITY   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bortezomib; Chitosan; Magnetic nanoparticles; Targeted drug delivery

Indexed keywords

BORTEZOMIB; CHITOSAN; INHIBITOR OF APOPTOSIS PROTEIN 2; POTASSIUM DIHYDROGEN PHOSPHATE; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURVIVIN; MAGNETITE NANOPARTICLE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; CYTOPLASM; CYTOTOXICITY; DOWN REGULATION; DRUG RELEASE; DRUG STABILITY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INFRARED SPECTROSCOPY; INTERNALIZATION; IONIC STRENGTH; OSMOTIC PRESSURE; PH; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATIC ELECTRICITY; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; XTT ASSAY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOCYTOSIS; GENE EXPRESSION REGULATION; GENETICS; IC50; IMMUNOHISTOCHEMISTRY; NEOPLASMS; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; BORTEZOMIB; CELL LINE, TUMOR; CELL PROLIFERATION; CHITOSAN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENDOCYTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MAGNETITE NANOPARTICLES; NEOPLASMS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84905104297     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.04.003     Document Type: Article

References (29)

1. ®: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8(6):508-513.
2. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
3. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., Sausville E., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clinical Cancer Res 2001, 7:1419-1428.
4. Cardoso F., Durbecq V., Laes J.F., Badran B., Lagneaux L., Bex F., et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006, 5(12):3042-3051.
5. Goel A., Dispensieri A., Greipp P.R., Witzig T.E., Mesa R.A., Russell S.J. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005, 33:784-795.
6. Eifel P.J. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 2006, 16(3):177-185.
7. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384(2):260-265.
8. Shubayev V.I., Pisanic T.R, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009, 61(6):467-477.
9. Sun C., Lee J.S.H., Zhang M.Q. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60:1252-1265.
10. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles forbiomedical applications. Biomaterials 2005, 26:3995-4021.
11. Andrade F., Antunes F., Vanessa Nascimento A., Baptista da Silva S., das Neves J., Ferreira D., et al. Chitosan formulations as carriers for therapeutic proteins. Curr Drug Dis Technol 2011, 8(3):157-172.
12. Grenha A. Chitosan nanoparticles: a survey of preparation methods. J Drug Target 2012, 20:291-300.
13. Dodane V., Vilivalam V.D. Pharmaceutical applications of chitosan. Pharmaceut Sci Technol Today 1998, 1(6):246-253.
14. Unsoy G., Yalcin S., Khodadust R., Gunduz G., Gunduz U. Synthesis optimization and characterization of chitosan coated iron oxide nanoparticles produced for biomedical applications. J Nanopar Res 2012, 14:1-13.
15. Pieróg M., Gierszewska-Druzyńska M., Ostrowska-Czubenko J. Effect of ionic crosslinking agents on swelling behavior of chitosan hydrogel membranes. Progress on Chemistry and Application of Chitin and its Derivatives 2009, Vol. XIV:75-82. Polish Chitin Society.
16. Berger J., Reist M., Mayer J.M., Felt O., Peppas N.A., Gurny R. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharmaceut Biopharmaceutics 2004, 57(1):19-34.
17. 4 polydopamine nanoparticles serve multipurpose as drug carrier, catalyst support and carbon adsorbent. ACS Appl Mater Interf 2013, 5:9167-9171.
18. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chem 2009, 21(1):5-13.
19. Huang M., Ma Z., Khor E., Lim L.Y. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharmaceut Res 2002, 19(10):1488-1494.
20. Park J.S., Han T.H., Lee K.Y., Han S.S., Hwang J.J., Moon D.H., et al. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J Controlled Release 2006, 115(1):37-45.
21. Ge Y., Zhang Y., He S., Nie F., Teng G., Gu N. Fluorescence modified chitosan coated magnetic nanoparticles for high-efficient cellular imaging. Nanoscale Res Lett 2009, 4(4):287-295.
22. Dandan Z., Yuquan Z., Yuqin J., Zuo Z.Y., Zuo M.Z. Effects of Bortezomib on inhibition of human cervical cancer SiHa cells and its mechanism. Prog Obstet Gynecol 2011, 20(2):113-115. 120.
23. Kvansakul M., Yang H., Fairlie W.D., Czabotar P.E., Fischer S.F., Perugini M.A., et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 2008, 15:1564-1571.
24. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011, 21(1):92-101.
25. Du H., Wolf J., Schafer B., Moldoveanu T., Chipuk J.E., Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem 2011, 286(1):491-501.
26. Dai H., Smith A., Meng X.W., Schneider P.A., Pang Y.P., Kaufmann S.H. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 2011, 194(1):39-48.
27. Roy N., Deveraux Q.L., Takashashi R., Salvesen G.S., Reed J.C. The cIAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997, 16:6914-6925.
28. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
29. Smith A.J., Dai H., Correia C., Takahashi R., Lee S.H., Schmitz I., et al. Noxa/Bcl-2 protein interactions contribute to Bortezomib resistance in human lymphoid cells. J Biol Chem 2011, 286(20):17682-17692.